01260 292 840
MODERN SLAVERY STATEMENT
We are committed to improving our practices to combat slavery and human trafficking. We recognise that slavery and human trafficking is a real yet hidden issue in our society. We will not tolerate slavery and human trafficking in our business or supply chain. We are committed to acting ethically and with integrity in all our business dealings and relationships and to implementing and enforcing effective systems and controls to ensure that any form of slavery is not taking place in our own business or supply chains.
We are a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital and markets. Our ultimate parent company is Quantum Pharma Plc with our head office based in England.
Quantum Pharma Group Limited (Group) operates through two divisions incorporating seven business units across seven sites in the UK and Europe, offering a portfolio of innovative and synergistic products and services:
Comprising three business units (Quantum Pharmaceutical Limited, UL Medicines Limited, Protomed Limited) which manufacture, procure and supply unlicensed medicines (specials) and special obtains as well as providing products and services to enhance medication adherence.
Comprising three business units (Colonis Pharma Limited, Lamda Pharma Limited, and Pern Consumer Products Limited) which develop and commercialise niche pharmaceutical products.
We operate a number of internal policies to ensure that we are conducting business in an ethical and transparent manner. These include:
Our supply chains
Our supply chains are based throughout the world and include suppliers of direct materials (active pharmaceutical ingredients, manufacturing and packaging), suppliers of indirect services (professional services, facilities, sales and marketing agencies) and distributors of our products.
We conduct due diligence on all suppliers assessed by our Quality Team as critical and/or major to the business before allowing them to become one of our suppliers. This due diligence includes assessing regulatory licences and certificates, compliance with such regulatory bodies, checks to determine the financial stability of the supplier as well as carrying out supplier audits, where appropriate.
We intend to take the following further steps to combat slavery and human trafficking:
This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes our Group's slavery and human trafficking statement for the current financial year.
Quantum Pharma Group Limited
Date: July 2017
Copyright© Protomed Limited 2014. All Rights Reserved. No part of this website may be reproduced without Protomed Limited's express consent.